curasan presents strategic investor

  • Investor with family ties into the Asian medical technology industry signs ten percent capital increase
  • Joint long-term development of the company planned
  • Acceleration of sales activities in China and the USA intended

Kleinostheim, 21.04.2015 – curasan AG (ISIN DE0005494538), a leading specialist for medical products in the field of bone and tissue regeneration, agreed with a strategic investor on signing a ten percent capital increase with the subscription rights of existing shareholders being excluded.

According to the decisions made yesterday evening by the CEO and the supervisory board of curasan AG the company’s share capital from conditional capital shall be increased at short notice by subscription of 934,604 shares of curasan AG at a price of 1.20 Euros per share by Mr. Yinan Xiong, born in Beijing (China) and residing in Richmond (British Columbia, Canada). The payment resulting in the amount of 1,132,324.80 Euros was confirmed by ODDO Seydler Bank AG, which executes the transaction. Immediately thereafter, the company will apply for the registration of the implementation of the capital increase, necessary for the effectiveness. The registration is targeted to take place still in May 2016, i.e. before the annual general meeting of the company on June 23, 2016.  Thereby, the registered share capital of curasan AG will be increased to 1,132,324.80 Euros.

Mr. Yinan Xiong has strong family ties into the Asian producing medical technology industry. ‘From this initial strategic investment in curasan being the worldwide technology leader in orthobiologic bone regeneration, numerous synergies will derive in the months and years ahead. Not only in Asia, but also in western markets’, Yinan Xiong explains the rational behind the investment. ‘We noticed the current path of realignment of curasan leads in the right direction. Together we will now achieve the goals ahead even faster.’

Following the management change end of 2014, curasan mainly focuses on optimizing distribution processes of its core products in the field of bone regeneration, in which the company still sets the worldwide acknowledged industry standard. In the past months the company successfully refocused its sales efforts on the most attractive international growth markets and initiated important registration processes in core markets in Asia and North-America.

For Michael Schlenk, CEO of curasan AG, the transaction conducted today is the most important milestone in the turnaround of the company so far. ‘It became soon obvious, the sales efforts of our products, which are requiring of a high level of explanation, would also financially be a challenge for our company. In the past months we have thus discussed ideas with a number of well-positioned medical technology companies, for which a strategic partnership would be of mutual benefit’, comments Schlenk. ‘The investment conducted today by Mr.  Yinan Xiong marks the start for an extensive partnership and the new basis for our growth in Asia.’

At the same time curasan plans to use the financial liquidity for a focused enhancement of its US sales activities. After prepared measures in its US market access strategy are currently being taken, the company shall inform about further steps near-term. For background information about the transaction executed today as well as expected steps ahead, CEO Michael Schlenk will be available for interested investors and members of the press in the course of a conference call on behalf of the release of the annual report 2015 on April 28th 2016, 1:30 PM CET.

 

Your contacts at curasan AG:
Ingo Middelmenne
Head of Investor Relations
+49 6027 40 900-45
+49 174 90 911 90
ingo.middelmenne@curasan.com

Andrea Weidner
Head of Corporate Communications
+49 6027 40 900-51
andrea.weidner@curasan.com

About curasan AG:

curasan AG develops, manufactures and markets biomaterials and other medical products in the field of bone and tissue regeneration. A pioneer in its industry, curasan is specialized primarily on synthetic bone grafting ­materials for dental and orthopaedic applications. Numerous patents and a comprehensive list of scientific documentation prove the clinical success of the products and the highly innovative strength of curasan. Surgically active dentists, implantologists and oral, maxillary and dentofacial surgeons, as well as orthopaedics, traumatologists and spinal column surgeons worldwide benefit from the broad range of the premium quality and user-oriented portfolio offered by the technology leader. curasan maintains its own high-tech facilities for research, development and manufacturing in Frankfurt/Main, Germany, which are approved by the Food and Drug Administration (FDA) and other international authorities. In addition to its headquarters, the company has a subsidiary, curasan Inc., in the Research Triangle Park, near Raleigh, N.C., USA.The shares of curasan AG are listed in the General Standard at the Frankfurt Stock Exchange. www.curasan.com